Video

Dr Clifford Goodman on Progress With the Move to Value-Based Payments

Different value-based payment approaches are evolving for different sorts of conditions, different sorts of financial circumstances, and other factors, explained Clifford Goodman, PhD, senior vice president and director, Center for Comparative Effectiveness Research, The Lewin Group.

This page contains sponsored advertising.

Different value-based payment approaches are evolving for different sorts of conditions, different sorts of financial circumstances, and other factors, explained Clifford Goodman, PhD, senior vice president and director, Center for Comparative Effectiveness Research, The Lewin Group.

Transcript

Has the move to value-based payments been happening as quickly as you expected?

With regard to the move toward value-based payments, it’s a couple interesting phenomena. One is that although most people might say that they’re disappointed in how quickly we’re moving to value-based payments, the very same people would probably say, “we didn’t realize how interesting and complex value-based payment is.”

So, although it seems to be taking some time, we’re also learning along the way. There’s no particular one right way to do value-based payment. Different value-based payment approaches are evolving for different sorts of conditions, different sorts of financial circumstances, and other factors are at work, as well. So, I would say that we are ramping up, but we’re learning how to do this piloting, experimenting, and getting feedback on what works.

In particular, some of the things that we’re noticing happen to be that it may be easy to conceptualize value-based payment, but how do you really operationalize it? Whose data are you going to use, how valid and rigorous are those data, who’s in charge of the data, who manages the data, who owns the data, and what sort of administrative burden is placed in the organization that’s charged with the data? And that’s just the data. So, again, overall ramping up gradually, but learning along the way. I’m still optimistic.

Related Videos
Parth Rali, MD
IMS Recap
Klaus Rabe, MD, PhD, chest physician and professor of medicine, University of Kiel
Screenshot during an interview with Aaron Adkisson, PharmD
Binod Dhakal, MD.
Ashraf Badros, MB, ChB.
Saad Z Usmani, MD, MBA, FACP.
Rahul Banerjee, MD, FACP
Anant Madabhushi, PhD.
Rahul Banerjee, MD, FACP.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo